Nexus Pharmaceuticals, Inc.

Delaware Court Blocks Ingenus from Pursuing Cancer Drug Patent Claims After Prior Invalidation

- A Delaware federal judge dismissed Ingenus Pharmaceuticals' patent infringement lawsuit against Hetero Labs over generic cyclophosphamide, ruling the company cannot pursue claims on a previously invalidated patent. - The court found that Ingenus already had a fair opportunity to defend US Patent No. 10,993,952's validity in a separate Illinois case against Nexus Pharmaceuticals and lost. - Judge Jennifer L. Hall granted summary judgment in favor of Hetero Labs, effectively barring Ingenus from relitigating the patent's validity in the Delaware case. - The ruling highlights the legal principle that prevents patent holders from repeatedly challenging generic drug makers over patents that have already been deemed invalid in prior litigation.